These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 15868148
1. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Wang H, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL. Cancer Chemother Pharmacol; 2005 Sep; 56(3):255-60. PubMed ID: 15868148 [Abstract] [Full Text] [Related]
2. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL. Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820 [Abstract] [Full Text] [Related]
3. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Li M, Wang H, Hill DL, Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R. Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493 [Abstract] [Full Text] [Related]
9. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G. Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [Abstract] [Full Text] [Related]
13. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor. Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, Kalgutkar AS. Xenobiotica; 2010 Jun; 40(6):369-80. PubMed ID: 20297923 [Abstract] [Full Text] [Related]
16. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R. Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296 [Abstract] [Full Text] [Related]
17. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Suckow RF, Smith TM, Perumal AS, Cooper TB. Drug Metab Dispos; 1986 Jan; 14(6):692-7. PubMed ID: 2877828 [Abstract] [Full Text] [Related]
18. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC. Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822 [Abstract] [Full Text] [Related]
19. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes. Quintieri L, Fantin M, Palatini P, De Martin S, Rosato A, Caruso M, Geroni C, Floreani M. Biochem Pharmacol; 2008 Sep 15; 76(6):784-95. PubMed ID: 18671948 [Abstract] [Full Text] [Related]
20. Disposition of abouthiouzine: a novel antihyperthyroid drug. Alkharfy KM, Khan RM, Al-Hadiya BM, Abou-Auda HS, Abou-Shaaban RR. Biopharm Drug Dispos; 2007 Apr 15; 28(3):105-11. PubMed ID: 17230598 [Abstract] [Full Text] [Related] Page: [Next] [New Search]